Clinical Trial Update: An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

View source ↗

Summary

This observational study evaluated cetuximab (Erbitux) in metastatic colorectal cancer patients refractory to irinotecan-containing therapy and the study has be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Colorectal Neoplasm | Status: TERMINATED